Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, United Kingdom.
Circ J. 2012;76(4):801-8. doi: 10.1253/circj.cj-11-1462. Epub 2012 Feb 29.
MitraClip® therapy is a percutaneous edge-to-edge plication of the mitral leaflets, mimicking the Alfieri surgical technique. MitraClip® implantation is a safe procedure, and survival outcomes in high-surgical-risk patients are superior to historical controls. Despite these results, questions remain concerning long-term efficacy and durability. The MitraClip® device has been studied in a safety and feasibility trial in the USA, a randomized pivotal trial against surgical mitral valve repair. Moreover, MitraClip® now has over 2 years of CE-mark approval and a rapidly expanding clinical experience in Europe, primarily in patients at high risk for surgery. A dedicated multidisciplinary team is necessary, as well as thoughtful patient selection, familiarity with the technical aspects of the procedure, including transesophageal ultrasound imaging and post-procedure monitoring. Currently available clinical data and procedural steps are herein reviewed. Because the MitraClip® procedure is still relatively new, continued investigation is required to further better define the patient populations that will benefit most.
MitraClip® 疗法是一种通过皮穿刺二尖瓣边缘对合的方法,模拟 Alfieri 手术技术。MitraClip® 植入术是一种安全的操作,对于高手术风险患者的生存结果优于历史对照。尽管有这些结果,但长期疗效和耐久性仍存在疑问。MitraClip® 装置已在美国进行了安全性和可行性试验研究,与外科二尖瓣修复术进行了随机关键试验。此外,MitraClip® 现在在欧洲获得了超过 2 年的 CE 标志批准和迅速扩大的临床经验,主要用于手术风险高的患者。需要一个专门的多学科团队,以及对患者的精心选择,熟悉该手术的技术方面,包括经食管超声心动图成像和术后监测。目前可获得的临床数据和手术步骤在此进行了回顾。由于 MitraClip® 手术仍相对较新,需要进一步研究以进一步更好地确定受益最大的患者人群。